| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_942782ef91e65ecc67141721d44d38eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate |
2020-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ef91413d3cecc75ea8e538eec6d1e27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b43d85de7f6ace8e5cbaedacb62f9a7d |
| publicationDate |
2020-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102150825-B1 |
| titleOfInvention |
Novel sglt-2 inhibitors cocrystal |
| abstract |
As a result of trying to improve the low stability and water solubility, which is a problem of empagliflozin, an empagliflozin/citric acid co-crystal with increased stability and water solubility by more than 60 times was developed. This empagliflozin/citric acid co-crystal is a new solid form that overcomes the stability and water solubility of the known empagliflozin crystal form, and is very useful as an optimal SGLT-2 inhibitory drug that can maximize its use as a drug. Do. |
| priorityDate |
2020-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |